Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Antitumor activity of the protein kinase inhibitor 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines

Fig. 6

Changes in cell cycle progression in cells after 48 h treatment with K164. Each bar represents the mean ± S.D. (n ≥ 5). The data obtained from FACS Canto II flow cytometer (BD Biosciences, San Jose CA, USA) were analyzed using MacCycle software to determine the percentage of cells in each phase of the cell cycle. Each bar represents the mean ± SD; asterisks indicate significance at p < 0.05 for comparison with the control

Back to article page